Diabetes mellitus types: Key genetic determinants and risk assessment

Dhilleswara Rao Vana¹, Dattatreya Adapa², Prasad VSS³, Amarendranath Choudhury⁴,⁵, Garima Ahuja⁶

¹Center for Excellence in Genomics, Madhurai Kamaraj University, Tamil Nadu, India
²Alumnus, Department of Microbiology, Food Science and Technology, GITAM University, Andhra Pradesh, India
³Alumnus, Biochemistry Division, National Institute of Nutrition, Hyderabad, Telangana, India
⁴Independent Researcher, Vizianagaram, Andhra Pradesh, India
⁵Alumnus, Department of Life Science and Bioinformatics, Assam University, Silchar, India
⁶Alumnus, Department of Biotechnology, Faculty of Engineering and Technology, Manav Rachna International Institute of Research and Studies, Faridabad, Haryana, India

Corresponding authors: Dhilleswara Rao Vana, Dattatreya Adapa

E-mail: drvana.biotech@gmail.com, dattu619@gmail.com

Genet. Mol. Res. 18 (2): gmr16039952

Received Jan 24, 2019
Accepted Feb 18, 2019
Published Mar 05, 2019

DOI: http://dx.doi.org/10.4238/gmr16039952

Copyright © 2018 The Authors. This is an open-access article distributed under the terms of the Creative Commons Attribution-ShareAlike (CC BY-SA) 4.0 License.

ABSTRACT.

The characteristic symptom of diabetes is consistently elevated levels of blood sugar. This is instigated either by complete lack of insulin production (type 1 diabetes), reduced level of insulin production (type 2 diabetes) or insulin resistance (inability of body cells to take up glucose). Other types of diabetes include maturity onset of diabetes of the young (MODY), a form of type 2 diabetes and gestational diabetes which affects pregnant women mostly in second or third trimester. The term type-3-diabetes is now being used for insulin resistance in brain. Apart from environmental and dietary causes which pose the risk of diabetes, genetic constitution and gene mutations execute the manifestation of
diabetes. So far, several hundreds of genes having genomic, metabolic and immunological functions have been associated with different forms of diabetes. Due to complexity in diabetes etiology, involvement of multiple genetic factors and overlap between phenotypes, the treatment for diabetes remains a major challenge. Single gene mutations can be potentially targeted therapeutically; however, the prevalence of single gene mutations in diabetic condition is rare. Comprehensive analysis of genes and genetic variants relevant to diabetes enables development of effective treatment or interventional strategies. The current literature survey was conducted and reviewed to identify studies that proposed the genetic basis for specific subtypes of diabetes and related complications. In addition, this review emphasizes the role of genome wide association studies and epigenetic factors. In the present review, we have identified some of the most significant protein encoding genes whose mutations have great impact in the development of diabetic condition. The characteristic features of these genes such as the risk level associated with the genes and inter-genic associations both in terms of position and functional proximity have been discussed. Additionally, genomic studies and epigenetic aspects have also been highlighted for wider comprehension of the diabetic condition from a genetic perspective. The present review would be of significance in prevention, screening, diagnosis, treatment and management of different forms of diabetes.

Keywords: Glycaemic index; Nutrients; Insulin resistance; Glycosylated haemoglobin; Type 1 diabetes; Type 2 diabetes; Insulin secretion; Insulin sensitivity; Receptor; Cellular signaling; Signal cascade; Gene.

Abbreviations: T1DM: Type 1 Diabetes Mellitus; T2DM: Type 2 Diabetes Mellitus; GES: Gestational Diabetes; MODY: Maturity Onset Diabetes of the Young.

INTRODUCTION

When fasting blood sugar level remains consistently above 126 mg/dL, then the condition is diagnosed as diabetes. Based on pooled analysis comprising of 751 population studies covering 146 countries representing 90% of worlds’ adult population, it was estimated that the age-standardized global prevalence of diabetes was 9% among men and 7.9% among women in 2014 (NCD-RisC, 2016). On a regional basis, the prevalence of diabetes was highest in both men and women of Oceania in 2014, crossing 15 percentage points. Among women, the lowest prevalence of 5.3% was observed in high-income western countries and among men; the lowest prevalence of age-standardized diabetes was 6.7% in sub-Saharan Africa (Figure 1). Co-existence of other clinical complications such as retinopathy, nephropathy, peripheral neuropathy, autonomic neuropathy, stroke and atherosclerosis leads to higher morbidity and mortality (American Diabetes Association, 2017; Forbes & Cooper, 2013; Mathers & Loncar, 2006; Shahi, Prasad, Imam, Abdul, & Jahangir, 2018).

Broadly, diabetes has been categorized as type-1 diabetes mellitus (T1DM), which is autoimmune mediated dysfunction of beta cells accounting for 5-10% of cases and type 2 diabetes mellitus (T2DM) which accounts for 90% of diabetes cases due to inadequate secretion of insulin (Atkinson, Eisenbarth, & Michels, 2014; Wild, Roglic, Green, Sicree, & King, 2004). The classification of diabetes has been revised based on latest developments in genetic understandings which revealed few monogenic disease forms including maturity onset diabetes of the young (MODY) and neonatal diabetes mellitus (NDM) accounting for 2-5% of cases around the
Diabetes mellitus types: Key genetic determinants and risk assessment

globe. The GWAS reinforced our understanding of fundamental genetics by identifying new risk variants associated with various subtypes of diabetes. However, identifying the low frequency traits, emerging genetic risks and association with environmental factors remain challenging for the researchers. Particularly, the identification of locus and interpretation of functional roles of the gene variants is very challenging in case of multiple loci harboring common variants associated with T2DM (Cooper, Krawczak, Polychronakos, Tyler-Smith, & Kehrer-Sawatzki, 2013; Tallapragada, Bhaskar, & Chandak, 2015).

![Figure 1. World-wide prevalence of diabetes, 2014. Source: Non-communicable disease NCD Risk Factor Collaboration (NCD-RisC, 2016).](image)

The present review summarizes the most recent outcomes from investigations of genetic mechanisms underlying the instigation, prognosis and manifestation of different subtypes of diabetes. The hypothesis remains to be tested as to whether any specific gene locus or group of gene loci exist that is/are common to different types of diabetes.
diabetes and if so, whether etiology of other forms of diabetes has any genetic association, either functionally or on positional basis, among the alleles associated with diabetes. It needs to be ascertained whether the manifestation of diabetes in general, is initiated by genetic polymorphism or alteration of metabolic pathway or both. Whether, there is any means of reversal of the process leading to permanent treatment or alleviation of the disease progression.

**T1DM and the associated genetic determinants**

T1DM is mostly due to the self-destruction of beta cells of pancreas; however, recent studies showed that the risk associated with at least one locus contributes to the familial clustering of T1DM. Advanced studies have found that clustering within major histocompatibility complex (MHC) located on chromosome 6 (6p21) is strongly (about 40%) associated with risk of T1DM. Recent genetic analyses and genome wide association studies (GWAS) revealed linkage of T1DM with many genes including insulin (INS), CTLA4, alongside HLA gene combinations (HLA-DQA1, HLA-DQB1 and HLA-DRB1) (Pociot et al., 2010; Rich, 2006).

In type I diabetes mellitus (T1DM), the body self-immune system destroys the islets of Langerhans (beta cells) in the pancreas, mainly mediated by T-cell (Jerram & Leslie, 2017), resulting either in decreased level or no synthesis/secretion of insulin. Multiple genes are involved in the manifestation of T1DM, mostly auto-immune regulatory genes (Brownlie, Zamoyska, & Salmond, 2018). Single nucleotide polymorphisms (SNPs) in about 40 genetic loci mostly associated with insulin secretion were linked with T1DM (Barrett et al., 2009). Epigenetic variations caused by environmental and dietary factors also influence the disease prognosis mediated by autoimmune response. In the past few years, much of research was done on the genetic and inter-genic determinants of T1DM and their interactions with causal agents.

Abnormal environmental and dietary patterns result in the modification of the nutrient and nutrient derived metabolite profile. This affects the normal course of metabolic homeostasis leading to alterations in the content and proportion of chromatic remodeling metabolites. Consequently, the DNA methylation/demethylation as well as histone acetylation/deacetylation pattern alter, triggering aberrant gene expression, energy metabolism/balance and disruption of immune tolerance. The autoimmune response involving genes that are specific to insulin producing β-cells lead to instigation of T1DM (Wang, Long, Chang, Zhao, & Lu, 2018). Polygenic effect comprises of about 30 to 60 susceptible genes distributed over 50 regions was reported (Sanyoura, Philipson, & Naylor, 2018). Incidence of monogenic T1DM accounts for 1-2% of total cases. The genetic risk score of T1DM has the potential to identify monogenic autoimmunity in individuals. The specificity, precision and the probability of success in gene therapy for monogenic autoimmunity mediated diabetes is much higher than polygenic autoimmunity (Johnson et al., 2018). Recently, differentially methylated circulating insulin DNA in the serum derived from beta cells are now being considered to evaluate the prognosis of T1DM (Liu, Tan, & Liu, 2017).

**Recent progress in genetic studies on T1DM**

FOXP3 encodes transcription factor in T cell function (Hwang et al., 2018). Mutation in the gene leads to dysregulation of immunity ultimately resulting in early onset of T1DM. Impaired functioning of FOXP3 encoded regulatory T cells leads to generation of CD4+ and CD8+ T effector cells which cause beta cell destruction (Schallenberg & Kretschmer, 2018).

Interleukin 6 (IL-6) is a major pro-inflammatory cytokine in different types of tissues. Based on a systematic review and meta-data analysis of case control studies, it was revealed that serum content of IL-6 in T1DM patients was substantially higher than the control subject group and there was no correlation between the IL-6 level and age/ethnicity/disease duration (Chen et al., 2017). IL-6, apart from immunoregulatory effects also affects glucose homeostasis by causing insulin resistance in other cell types (Rehman et al., 2017).

A lot of variation exists in the etiology of T1DM. Insulin gene (INS) encodes pro-insulin which after post translational modification form insulin. Insulin is required for normal glucose homeostasis. Mutation in INS gene
leads to misfolding resulting in hyperglycaemia and this phenomenon is commonly called as autoantibody-negative type 1 diabetes which is frequently observed in neonates and youth (Arunagiri et al., 2018; Barbetti et al., 2017).

**ITPR3** gene encodes inositol 1,4,5-trisphosphate which is a receptor that mediates release of intracellular calcium. Polymorphism in this gene contributes to the risk of T1DM. In beta cells, when the voltage dependent Ca\(^{2+}\) channel opens the calcium ions enter into the cytoplasm thus enabling the secretion of insulin out of the cell. Since **ITPR3** encodes receptor that regulates calcium transport, it is hypothesized that polymorphism in **ITPR3** dysregulates insulin secretion (Rorsman & Ashcroft, 2018).

**OAS1** gene encodes protein that activates RNAase that cleaves the viral RNA, thus conferring anti-viral property. The gene also affects other cellular process such as apoptosis, cell differentiation and gene regulation. The expression of the **OAS1** gene was found to be significantly enhanced in T1DM patients when compared to normal subjects (Field et al., 2005) indicating that genetic response to viral infection may predispose the individual to T1DM. Single nucleotide polymorphism alters splicing (rs10774671) in **OAS1** gene. Alternate splicing results in multiple transcript variants with different enzymatic activities. Substitution of serine/glycine in **OAS1** exon 3 was identified as the most probable functional variant of the gene associated with increased enzymatic activity as well as with T1DM in case-sibling control study (Tessier et al., 2006). Later, it was observed that within **OAS1** gene, A/G splice-site single nucleotide polymorphism (SNP; rs10774671) was associated with protective influence against T1DM among unaffected siblings (Smyth et al., 2006).

Protein tyrosine phosphatase N22 (**PTPN22**) gene encodes protein lymphoid tyrosine phosphatase (Lyp) that regulates signal transduction and play an important role in cellular differentiation. A missense mutation in the position 1858 from cytosine to thymidine in this gene leads to a change from Arg at position 620 to Trp which is associated with several autoimmune disorders that include T1DM. This allelic variation associated with autoimmunity was found to impair \(\beta\)-cell signaling which is characterized by proliferation deficit, reduced protein phosphorylation thus contributing to autoimmunity which affects \(\beta\)-cell maturation (Arechiga et al., 2009). Such intrinsic deficit in \(\beta\)-beta cell functioning could lead to T1DM.

Human leukocyte antigen (**HLA**) genes are the most impactful genes that encodes major histocompatibility complex (**MHC**) proteins involved in T1DM (Redondo, Steck, & Pugliese, 2018). **HLA** class II and class I genes have been identified as the most significant genetic risk factors associated with T1DM (Pociot et al., 2010). Polymorphism in non-**HLA** genes **INS**, **PTPN22**, **CTLA4**, and **IL2RA** are also genetic risk factors of T1DM. **HLA-DQA1** and **HLA-DQB1** genes transcribe and translate into two different proteins that bind together to form functional antigen-binding DQβ heterodimer which displays foreign peptides to the immune system (Caillat-Zucman, 2017). The role of auto-islet immunity mediated T1DM is increased by specific **HLA DR/DQ** allele. Highest risk for T1DM was found to be the **DR3-DQ8** (DQ8 is DQA1*0301, DQB1*0302) heterozygous genotype (Aly et al., 2006). In another study, both **HLA-DRB1*04** and **-DRB1*03** frequencies were significantly higher among T1DM patients than in controls (Grubic et al., 2018). Variability in these genes is represented by several alleles that confer immunity to wide range of foreign antigens. Mutations in **HLA** genes override polygenic prevention of autoimmunity which makes human genome prone to T1DM (Noble & Valdes, 2011). The exact sequence of events and the mechanism of susceptibility are not clear as **HLA** refers to region in the genome constituted by several genes encoding different functional products. The reversal of the autoimmune process post onset is impractical. Therefore, prior diagnosis of the risk groups and prevention remains the effective strategy. Non **DR/DQ** loci within the **MHC** such as **HLA-DP** have been identified that have the potential to predict T1DM (Baschal & Eisenbarth, 2008).

**Recent advances in T2DM genetics**

Unlike T1DM, T2DM has no definitive cause; therefore, it is necessary to conduct multitude of studies to estimate the effects of risk factors such as age, sex, diet, physical activity/inactivity, familial history, genetics and ethnicity. The disease progression rate and associated complications are not similar across all T2DM patients; moreover, there are many factors involved in insulin resistance. This indicates that T2DM is a complex disease with coalition of metabolic disorders and combination of multiple intermediary traits. Hence, there is a strong rationale to...
change the pace of future studies to identify genetic association of T2DM (Ismail-Beigi et al., 2010; Thomas & Philipson, 2015; Zoungas et al., 2009). Genetic susceptibility of this multi-factorial disease has been studied as early as in 1980s which demonstrated a strong association of genetic components (Barnett, Ef, Leslie, & Pyke, 1981; Hansen & Pedersen, 2004). Studies conducted to identify candidate genes associated with T2DM have been employed and genes influencing the β-cell function were identified (McCarthy, 2004). Genome-wide familial linkage-based approaches showed chromosomal positioning of genes such as HNF4A, CAPN10, ENPP1, ADIPOQ and TCF7L2, (Jose C Florez et al., 2012). GWAS focused on multiple common variants that are significant contributors in disease risk and progression. Subsequently, many consortiums were formed to perform large-scale studies to characterize the genetic basis of T2DM. DIAbetes Genetics Replication and Meta-analysis Consortium (DIAGRAM) is one of earliest study groups formed in the Europe which identified 31 novel loci that are associated with T2DM risk (http://diagram-consortium.org/about.html). Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) identified loci for fasting plasma glucose, fasting insulin, 2 h glucose, and HbA1c traits (Dupuis et al., 2010; Manning et al., 2012; Morris et al., 2012; Saxena et al., 2010; Scott et al., 2012; Voight et al., 2010) (https://www.magicinvestigators.org/). Genetic Investigation of Anthropometric Traits (GIANT) revealed hundreds of loci that are associated with obesity related/associated traits (Berndt et al., 2013; Locke et al., 2015; Randall et al., 2013; Shungin et al., 2015).

T2DM is a complex metabolic disorder involving multiple genes which are spatially distributed across different chromosomes and associated with diverse cellular signaling and metabolic pathways (Table 1). Environmental and dietary factors influence the risk of T2DM. However, genetic factors also play a significant role in the manifestation of T2DM. This is corroborated by the fact that a positive family history with diabetes confers a 2.5 fold greater risk for T2DM and about 15 to 25% of the first degree relatives of T2DM patients develop impaired glucose tolerance that may lead to T2DM (Stumvoll, Goldstein, & van Haeften, 2005). The risk of developing T2DM is about 38%, if one parent has T2DM (Pierce, Keen, & Bradley, 1995) and about 60% if both the parents are diabetic (Tattersal & Fajans, 1975). Description of some of the most relevant T2DM associated genes in terms of gene function under normal health condition, etiology, prevalence, risk alleles, type of genetic variation - their functional effects in disease condition are provided in this review.

<table>
<thead>
<tr>
<th>CHR</th>
<th>GEN</th>
<th>DESCRIPTION</th>
<th>FUNCTION</th>
<th>LOCATION</th>
<th>START</th>
<th>END</th>
<th>LENGTH</th>
<th>EXONS</th>
<th>TYPE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>PTPN22</td>
<td>Protein Tyrosine Phosphatase, Non-Receptor Type 22</td>
<td>Immunological</td>
<td>1p13.2</td>
<td>11381381</td>
<td>11387176</td>
<td>57950</td>
<td>24</td>
<td>T1DM</td>
</tr>
<tr>
<td>2</td>
<td>CTLA4</td>
<td>Cytotoxic T-Lymphocyte Associated Protein 4</td>
<td>Immunological</td>
<td>2q33.2</td>
<td>20386778</td>
<td>20387396</td>
<td>6172</td>
<td>4</td>
<td>T1DM</td>
</tr>
<tr>
<td>2</td>
<td>GCKR</td>
<td>Glucokinase Regulator</td>
<td>Metabolic</td>
<td>2p23.3</td>
<td>27496839</td>
<td>2752689</td>
<td>26850</td>
<td>20</td>
<td>MODY2</td>
</tr>
<tr>
<td>2</td>
<td>IRS1</td>
<td>Insulin Receptor Substrate 1</td>
<td>Metabolic</td>
<td>2q36.3</td>
<td>22673131</td>
<td>22679879</td>
<td>67473</td>
<td>2</td>
<td>T1DM, GES</td>
</tr>
<tr>
<td>2</td>
<td>KLF11</td>
<td>Knuckle Like Factor 11</td>
<td>Transcription factor</td>
<td>2p25.1</td>
<td>10043555</td>
<td>10054836</td>
<td>11281</td>
<td>6</td>
<td>MODY7</td>
</tr>
<tr>
<td>2</td>
<td>NEUR</td>
<td>Neuronal Differentiation 1</td>
<td>Transcription factor</td>
<td>2p31.3</td>
<td>18166829</td>
<td>18168066</td>
<td>12370</td>
<td>4</td>
<td>MODY6</td>
</tr>
<tr>
<td>3</td>
<td>APPL1</td>
<td>Adaptor Protein, Phosphotyrosine Interacting With PH Domain And Leucine Zipper 1</td>
<td>Receptor</td>
<td>3p14.3</td>
<td>57227373</td>
<td>5723471</td>
<td>45734</td>
<td>23</td>
<td>MODY14</td>
</tr>
<tr>
<td>3</td>
<td>CCR5</td>
<td>C-C Mot Chemokine Receptor 5 (Gene/Pseudogene)</td>
<td>Immunological</td>
<td>3p21.31</td>
<td>46370142</td>
<td>46376206</td>
<td>6064</td>
<td>3</td>
<td>T1DM</td>
</tr>
<tr>
<td>3</td>
<td>GDF2</td>
<td>Insulin Like Growth Factor 2 Mina Binding Protein 2</td>
<td>Genetic</td>
<td>3q27.2</td>
<td>18564315</td>
<td>18582505</td>
<td>181925</td>
<td>24</td>
<td>GES</td>
</tr>
<tr>
<td>3</td>
<td>PPARG</td>
<td>Peroxisome Proliferator Activated Receptor Gamma</td>
<td>Genetic</td>
<td>3p25.2</td>
<td>12287485</td>
<td>12471054</td>
<td>183569</td>
<td>14</td>
<td>T1DM</td>
</tr>
<tr>
<td>4</td>
<td>WFS1</td>
<td>Wolfram I Transmembrane Glycoprotein</td>
<td>Metabolic</td>
<td>4p16.1</td>
<td>6260368</td>
<td>6303265</td>
<td>42897</td>
<td>10</td>
<td>T2DM</td>
</tr>
<tr>
<td>6</td>
<td>CDK4L</td>
<td>CDK5 Regulatory Subunit Associated Protein 1 Like 1</td>
<td>Genetic</td>
<td>6p22.3</td>
<td>20534457</td>
<td>21232404</td>
<td>697947</td>
<td>22</td>
<td>GES</td>
</tr>
<tr>
<td>6</td>
<td>HLA-DQ</td>
<td>Major Histocompatibility Complex, Class II, DQ Alpha 1</td>
<td>Immunological</td>
<td>6p21.32</td>
<td>32657406</td>
<td>32654846</td>
<td>17440</td>
<td>6</td>
<td>T1DM</td>
</tr>
</tbody>
</table>

Table 1. Genetic features of different types of diabetes.
Peroxisome proliferator-activated receptor gamma (PPAR-γ) gene encodes nuclear receptor protein that regulates adipocyte differentiation and glucose homeostasis. PPAR-γ was found to be down regulated in T2DM and in colon cancer as well (Lecarpentier, Claes, Vallée, & Hébert, 2017). PPAR-γ is activated by certain fatty acids, prostanoids, and thiazolidinediones (Olefsky, 2000). After activation by a ligand, the nuclear receptor protein regulates the transcription of other genes associated with fat partitioning into adipocyte and free fatty acid oxidation thus lowering free fatty acid content in the blood. Polymorphic variant of the Pro12Ala in PPAR-γ is highly prevalent (75%) in white people (Stumvoll et al., 2005). Heterozygous negative dominant mutations causing functional loss in PPAR-γ leads to dyslipidemia, insulin resistance and hyperglycaemia (Agostini et al., 2018). Point mutations in PPAR-γ lead to a gradation of metabolic response. Supplementation of flaxseed oil for about three months was found to significantly improve PPAR-γ gene expression in diabetic patients with coronary heart disease (Hashemzadeh et al., 2017). PPAR-γ protein has the potential to serve as anti-diabetic molecular target (Kerru, Singh-Pillay, Awolade, & Singh, 2018).

### Table 1: Diabetes mellitus types: Key genetic determinants and risk assessment

<table>
<thead>
<tr>
<th>Rank</th>
<th>Gene</th>
<th>Type</th>
<th>Effect</th>
<th>Risk of T2DM</th>
<th>SNP in</th>
<th>GES</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>HLA-DB1</td>
<td>Major Histocompatibility Complex, Class II, DQ Beta 1</td>
<td>Immuno</td>
<td>6p21.32</td>
<td>32659464</td>
<td>7225</td>
</tr>
<tr>
<td>6</td>
<td>HLA-DRB1</td>
<td>Major Histocompatibility Complex, Class II, DR Beta 1</td>
<td>Immuno</td>
<td>6p21.32</td>
<td>32578769</td>
<td>32589386</td>
</tr>
<tr>
<td>6</td>
<td>ITPR3</td>
<td>Inositol 1,4,5-Trisphosphate Receptor Type 3</td>
<td>Metab</td>
<td>6p21.31</td>
<td>33621333</td>
<td>33696574</td>
</tr>
<tr>
<td>6</td>
<td>SUM O4</td>
<td>Small Ubiquitin-Like Modifier 4</td>
<td>Metab</td>
<td>6q25.1</td>
<td>1490035</td>
<td>14904104</td>
</tr>
<tr>
<td>7</td>
<td>GCK</td>
<td>Glucokinase</td>
<td>Metab</td>
<td>7p13</td>
<td>44143213</td>
<td>44189439</td>
</tr>
<tr>
<td>7</td>
<td>GCK</td>
<td>Glucokinase</td>
<td>Enz</td>
<td>7p13</td>
<td>4443213</td>
<td>444189439</td>
</tr>
<tr>
<td>7</td>
<td>IL6</td>
<td>Interleukin 6</td>
<td>Immuno</td>
<td>7p15.3</td>
<td>22725889</td>
<td>22732020</td>
</tr>
<tr>
<td>7</td>
<td>PAI4</td>
<td>Plasminogen Activator Inhibitor 4</td>
<td>Tran factor</td>
<td>7q32.1</td>
<td>1276102 4</td>
<td>12761819</td>
</tr>
<tr>
<td>8</td>
<td>BLK</td>
<td>B-Cell Lymphoma 6</td>
<td>Receptor</td>
<td>8p23.1</td>
<td>11493991</td>
<td>11564604</td>
</tr>
<tr>
<td>8</td>
<td>CEL</td>
<td>Carboxyl Ester Lipase</td>
<td>Enz</td>
<td>9q34.13</td>
<td>13306197</td>
<td>13307186</td>
</tr>
<tr>
<td>8</td>
<td>IL2RA</td>
<td>Interleukin 2 Receptor Subunit Alpha</td>
<td>Immunog</td>
<td>10p15.1</td>
<td>6010694</td>
<td>6062370</td>
</tr>
<tr>
<td>10</td>
<td>TCF7L2</td>
<td>Transcription Factor 7 Like 2</td>
<td>Gene</td>
<td>10q25.2-2q5.3</td>
<td>11295022</td>
<td>11316767</td>
</tr>
<tr>
<td>11</td>
<td>INS</td>
<td>Insulin</td>
<td>Metab</td>
<td>11p15.5</td>
<td>2159779</td>
<td>2161209</td>
</tr>
<tr>
<td>11</td>
<td>INS</td>
<td>Insulin</td>
<td>Hormone</td>
<td>11p15.5</td>
<td>2159779</td>
<td>2161209</td>
</tr>
<tr>
<td>11</td>
<td>KCNJ11</td>
<td>Potassium Voltage-Gated Channel Subfamily J Member 11</td>
<td>Metab</td>
<td>11p15.1</td>
<td>17385246</td>
<td>17389331</td>
</tr>
<tr>
<td>11</td>
<td>KCNJ11</td>
<td>Potassium Voltage-Gated Channel Subfamily J Member 11</td>
<td>Transporter</td>
<td>11p15.1</td>
<td>17385246</td>
<td>17389331</td>
</tr>
<tr>
<td>11</td>
<td>KCNJ11</td>
<td>Potassium Voltage-Gated Channel Subfamily J Member 11</td>
<td>Metab</td>
<td>11p15.5-p15.4</td>
<td>2444991</td>
<td>2849110</td>
</tr>
<tr>
<td>11</td>
<td>MINK1</td>
<td>Metastin Receptor 1B</td>
<td>Metab</td>
<td>11q14.3</td>
<td>92969623</td>
<td>92986241</td>
</tr>
<tr>
<td>12</td>
<td>HNF1A</td>
<td>HNF1 Homeobox A</td>
<td>Genetic</td>
<td>12q24.31</td>
<td>12097768</td>
<td>12100251</td>
</tr>
<tr>
<td>12</td>
<td>OAS1</td>
<td>2'-5'-Oligoadenylate Synthetase 1</td>
<td>Immunog</td>
<td>12q24.13</td>
<td>11290677</td>
<td>11293219</td>
</tr>
<tr>
<td>13</td>
<td>IRS2</td>
<td>Insulin Receptor Substrate 2</td>
<td>Metab</td>
<td>13q34</td>
<td>10975838</td>
<td>10978656</td>
</tr>
<tr>
<td>13</td>
<td>PDX1</td>
<td>Pancreatic And Duodenal Homebox 1</td>
<td>Transcription factor</td>
<td>13q12.2</td>
<td>27919982</td>
<td>27926314</td>
</tr>
<tr>
<td>17</td>
<td>HNF1B</td>
<td>HNF1 Homeobox B</td>
<td>Transcription factor</td>
<td>17q12</td>
<td>3766431</td>
<td>37745078</td>
</tr>
<tr>
<td>20</td>
<td>HNF4A</td>
<td>Hepatocyte Nuclear Factor 4 Alpha</td>
<td>Genetic</td>
<td>20q13.12</td>
<td>44355801</td>
<td>44432845</td>
</tr>
<tr>
<td>20</td>
<td>HNF4A</td>
<td>Hepatocyte Nuclear Factor 4 Alpha</td>
<td>Transcription factor</td>
<td>20q13.12</td>
<td>44355801</td>
<td>44432845</td>
</tr>
<tr>
<td>X</td>
<td>FOXF3</td>
<td>Forkhead Box P3</td>
<td>Immunog</td>
<td>Xp11.23</td>
<td>49250436</td>
<td>49264932</td>
</tr>
</tbody>
</table>

**Note:** TIDM: Type 1 Diabetes Mellitus; T2DM: Type 2 Diabetes Mellitus; GES: Gestational Diabetes; MODY: Maturity Onset Diabetes of the Young.


**PPAR-γ** gene encodes nuclear receptor protein that regulates adipocyte differentiation and glucose homeostasis. PPAR-γ was found to be down regulated in T2DM and in colon cancer as well (Lecarpentier, Claes, Vallée, & Hébert, 2017). PPAR-γ is activated by certain fatty acids, prostanoids, and thiazolidinediones (Olefsky, 2000). After activation by a ligand, the nuclear receptor protein regulates the transcription of other genes associated with fat partitioning into adipocyte and free fatty acid oxidation thus lowering free fatty acid content in the blood. Polymorphic variant of the Pro12Ala in PPAR-γ is highly prevalent (75%) in white people (Stumvoll et al., 2005). Heterozygous negative dominant mutations causing functional loss in PPAR-γ leads to dyslipidemia, insulin resistance and hyperglycaemia (Agostini et al., 2018). Point mutations in PPAR-γ lead to a gradation of metabolic response. Supplementation of flaxseed oil for about three months was found to significantly improve PPAR-γ gene expression in diabetic patients with coronary heart disease (Hashemzadeh et al., 2017). PPAR-γ protein has the potential to serve as anti-diabetic molecular target (Kerru, Singh-Pillay, Awolade, & Singh, 2018).
Peralta-Leal, Durán-González, & Meza-Espinoza, 2017). Gly971Arg substitution in this gene leads to impaired signaling and thus insulin resistance. Recently, it was observed that up-regulated hepatic mRNA (miR-222) in the insulin resistant state represses IRS1 gene expression leading to impaired insulin signaling (Ono et al., 2018).

**IRS2** gene encodes protein that functions as an adaptor to insulin receptor in order to activate kinase cascade in insulin signaling. Therefore, repression of IRS2 gene leads to insulin resistance (Zhang & Sun, 2009). Recently, it was observed that hyperglycaemia alters expression of IRS proteins in nerve cells leading to impaired insulin signal cascade and diabetic peripheral neuropathy (Manu, Rachana, & Advirao, 2017). Among the recent findings, polymorphism in Gly1057Asp of IRS-2 gene was found to be associated with T2DM (Ay et al., 2018).

Recently, Kleiner et al. have reported that loss of function mutation in SLC30A8 which encodes protein that transports zinc into insulin containing secretory granules in β-cells may exert beneficial influence on insulin secretion under hyperglycaemic conditions (Kleiner et al., 2018). Zhong et al. have observed that silencing of DDX1 gene (encoding multifunctional protein) impairs calcium influx and insulin secretion in β-cells (Zhong, Li, Zhou, Xu, & Wang, 2018). Juan-Mateu et al. have noted that SRp55 (a splicing factor) regulated by GLIS3 functions for splicing of genes involved in cell survival, insulin secretion, and c-Jun N-terminal kinase (JNK) signaling. Depletion of SRp55 inhibits β-cell mitochondrial functioning, decreases insulin secretion and triggers β-cell apoptosis (Juan-Mateu et al., 2018).

**WFS1** gene encodes wolframin glycoprotein located in endoplasmic reticulum membrane which regulates the amount of calcium within the cell thus enabling endoplasmic reticulum to function in protein folding. Allelic mutation in WFS1 gene causes autosomal recessive wolfram syndrome characterized by non-auto-immune diabetes (Bansal, Boehm, & Darvasi, 2018). Hofmann et al. have emphasized that wolfram syndrome is caused by reduced level of protein expression rather than mutant wolframin because of rapid decay of WFS1 nonsense transcripts as well as reduced content and/or reduced half-life of steady state wolframin in case of missense mutation R629W (Hofmann, Philbrook, Gerbitz, & Bauer, 2003). Bansal et al. identified a low frequency missense coding variant (c.1672C>T, p.R558C) in the WFS1 gene among Jewish individuals that causes wolfram syndrome (Bansal et al., 2018). Li et al. also identified a mutation in WFS1 gene in exon 8 (c.1760G > A) that caused diabetes in a Chinese patient (Li et al., 2018). Similarly, several mutations have been identified by Rigoli et al. that were linked to T2DM (Rigoli, Bramanti, Di Bella, & De Luca, 2018). Frank et al. have established a strong association between SNP in WFS1 locus, rs10010131, with risk of T2DM among European population (Franks et al., 2008). Similarly, Minton et al. have also observed that WFS1 gene variant influences susceptibility to T2DM among UK population and R456-H611 haplotype was highly frequent in type 2 diabetic subjects (Minton et al., 2002).

**HNF1A** encodes transcription factor that expresses pancreatic and hepatic genes. Mutation in HNF1A accounts for upto 3% of diabetic cases among children (Rama Chandran et al., 2018). The genetic variant of HNF1A gene is among the 40 confirmed variant loci associated with T2DM (McCarthy, 2010). Nuli et al. reported that HNF1A gene variants of rs2464196, rs1169288 and rs1169289 might interact with smoking and dietary factors in conferring risk of T2DM in the Uyghur population (Nuli et al., 2018). The variant rs2259816 (HNF1A) was found to be significantly associated with risk of coronary heart disease among T2DM patients (De Rosa et al., 2018). However, some studies have noted that the genetic variants of HNF1A affecting insulin secretion were found to be only associated with T2DM in non-obese individuals. Based on whole-exome sequencing, a low frequency missense variant of HNF1A was found to be associated with T2DM prevalence in population of Latinos (Estrada et al., 2014). Meta-analytical studies revealed two missense SNPs of A98V and I27L associated with T2DM that were reported to manifest a decrease in insulin secretion (Holmkvist et al., 2006).

**HNF4A** encodes protein that regulates the transcription of HNF1A thus regulating upstream hepatic gene expression. Although the variants of HNF4A are rare (Huerta-Saenz, Saunders, & Yan, 2018), they were identified as putative causal factor for T2DM affecting β-cell functioning (Kooner et al., 2011; Sladek et al., 2007). Allelic variant of rs4812829 in HNF4A was strongly associated with β-cell functioning and proinsulin, whereas rs1800961 was linked with lipid and proinsulin suggesting insulin secretion and insulin resistance mechanisms (Udler et al., 2018).
Diabetes mellitus types: Key genetic determinants and risk assessment

2018). The risk allele of rs4812829 in HNF4A was identified as an SNP that is strongly associated with T2DM among South Asian population (Kooner et al., 2011). However, it was observed that the variants of HNF4A were associated with a very small percentage of T2DM risk (J C Florez, 2008).

The genetic similarity between T1DM and T2DM is that both belong to polygenic variations and are caused due to the interactions between genetic and environmental factors. The basic determinants of diabetic condition and their effects are presented in Figure 2.

![Figure 2. Classification of genetic effects.](image)

**Genetics challenges of monogenic diabetes**

The monogenic diabetes is a rare heterogeneous group of disorders arising due to defects in single gene, where hyperglycemia is observed due to defects in insulin secretion or decrease in beta cell mass or both (Schwitzgebel, 2014; Thomas & Philipson, 2015; Wiley, 2016). MODY is a form of monogenic diabetes, which is diagnosed at the childhood or early adulthood (before 25 years of age) stages. MODY is clinically and genetically heterogeneous, non-insulin dependent and familial diabetes which is caused due to the autosomal dominance inheritance. According to American Diabetes Association (ADA) guidelines, monogenic diabetes can be considered, when an individual does not have T1DM and T2DM features and diagnosed before 6 months of life with a strong familial history of diabetes, and stable/mild elevated fasting blood glucose levels (American Diabetes
Association, 2017). Around 13 genes are associated with risk of MODY and mutations in glucose sensor enzyme glucokinase and 5 transcription factors are involved in regulation of adult β-cell function and a role in MODY progression. It is estimated that the mutations in GCK and HNF1 homeobox A (HNF1A) accounts for approximately 50% cases and mutations in HNF4A and HNF1B accounts for 10% cases while the genetic causes for few sub-types of MODY remains unknown (Ellard, Bellanne-Chantelot, & Hattersley, 2008; Rubio-Cabezas et al., 2014). Recent studies employed high-throughput sequencing technologies sequenced the genes associated with diabetes and obesity on large samples to identify target gene candidates (Bonnefond et al., 2014; Froguel, 2015; Molven & Njolstad, 2011). A Illumina high-throughput sequencing technology study sequenced a large set of genes to identify the association between monogenic diabetes and T2DM. In this study, on an overall basis, 22 genes were found to be associated with monogenic forms of diabetes which includes 13 MODY, 6 genes associated with recessive diseases that include diabetes as a phenotype and 3 genes within which heterozygous mutations lead to diabetes (Bonnefond et al., 2014; Ellard et al., 2013; Flannick et al., 2013). Next generation sequencing, whole genome sequencing and exome sequencing provided more insights into low frequency risk variants and disease causing mechanisms (Claussnitzer et al., 2014; Flannick et al., 2014; Majithia et al., 2014; Steinthorsdottir et al., 2014).

Monogenic diabetes forms are rare and caused due to mutation in single gene and in many cases the mutations are inherited from one or both parents. MODY and NDM are two common subtypes of monogenic diabetes (Barbetti & D’Annunzio, 2018). Most recent GWA studies showed that there are loci and mechanisms that are common in MODY and T2DM (Biesecker, 2018). Mapping function approaches found that cis-regulation is a common mechanism associated with affected transcriptional enhancers and silencers (Fogarty, Cannon, Vadlamudi, Gaulton, & Mohlke, 2014; Fogarty, Panhuis, Vadlamudi, Buchkovich, & Mohlke, 2013; López Rodríguez et al., 2017). There are different genes associated with MODY and few of them have a strong correlation with other forms of diabetes. In addition, clinical features of MODY depend on the type of gene mutation (Gardner & Tai, 2012). It is believed that in certain types of mutations, there are no symptoms of diabetes and or there is no development of associated complications (https://www.who.int/genomics/about/Diabetis-fin. pdf). As of now, about 14 genes responsible for the onset of MODY were reported and few of them also pose a risk for NDM (Table 1).

According to Biesecker, T2DM or adult onset diabetes is associated with several genes with common susceptibility variants which can lead to single gene or Mendelian form of diabetes, for example glucokinase (GCK) related T2DM (Biesecker, 2018). Therefore, such rare forms of T2DM need to be differentiated from single gene MODY. The diagnosis of MODY which is an atypical autoimmune form of diabetes is challenging due to clinical and genetic heterogeneity. Recently, Pace et al. reported a rare missense mutation in exon 8 of HNF1β (p.Arg527Gln) in obese Maltese women with autoimmune diabetes revealing monogenic diabetes could contribute substantially to disease burden (Pace, Craus, Felice, & Vassallo, 2018).

HNF1β gene mutation leads to MODY5 which is a multi-systemic syndrome and a monogenic form of diabetes. In adults, HNF1A-MODY is considered as the most frequently observed form of monogenic diabetes which can be potentially misdiagnosed as T1DM or T2DM; hence, genetic diagnosis is required. Pavic et al. attempted to estimate the prevalence of HNF1A-MODY among adults below 45 years of age with HNF1A allele variants in Croatia (Pavic et al., 2018). The study revealed the prevalence rate of HNF1A-MODY was 66 cases per million which was similar to other European countries.

Pollak et al. have recently reported that GCK gene sequencing resulted in accurate molecular diagnosis of MODY2 and facilitated adequate medical treatment in an affected Chilean family (Pollak C et al., 2017). Khelifa et al. have reported that GCK and HNF1A mutations are most frequently observed among Caucasians and attempted to evaluate the etiology of MODY in Tunisia (Ben Khelifa et al., 2018). After screening for mutations in GCK, HNF1A, HNF4A and INS genes, it was found that there were no mutations in HNF1A and INS genes suggesting the probable involvement of other unidentified genes (Ben Khelifa et al., 2018).

Genetic variants of gestational diabetes

Genetics and Molecular Research 18 (2): gmr16039952
Gestational diabetes is a condition where normo-glycemic women prior to pregnancy develop glucose intolerance in late gestational period resulting in subclinical manifestation of metabolic dysfunction. About 50 to 60% decrease in the insulin sensitivity can be observed during normal pregnancy (Catalano, 2014). Decreased β-cell functioning (lower secretion of insulin) and the lack of insulin sensitivity or increased insulin resistance in peripheral tissues leads to hyperglycemia in such women. In normal women with glycemic tolerance, this is a transient phase and gets reversed after giving birth. However, in women with gestational diabetes, the inflammatory response and low insulin sensitivity continues post-partum due to reduced tyrosine phosphorylation of insulin receptor substrate 1 (IRS1). Gene array studies have emphasized that alteration of gene expression pattern in lipid metabolism leading to hyperlipidemia were mainly involved in development of gestational diabetes (Catalano, 2014). Gestational diabetes manifests in the late second trimester period. The prevalence of gestational diabetes is about 1 to 3% of all the pregnancies. Women with previous history of gestational diabetes have a high risk of developing non-insulin dependent diabetes mellitus (NIDDM) (Damm, 1998). In a recent study comprising of 262 Euro-Brazilian pregnant women, it was observed that polymorphism of rs17567 (Gln279Arg) in Metalloproteinase 9 Gene (MMP9) was associated with gestational diabetes (Costa et al., 2018). Recently, Tagoma et al. have found that about 15 miRNA involved in 41 pathways were up-regulated in women with gestational diabetes (Tagoma, Alnek, Kirss, Uibo, & Haller-Kikkatalo, 2018). Among them, pathways associated with fatty acid biosynthesis and metabolism were the most relevant to gestational diabetes. The study concludes that increased plasma miR-195-5p miRNA is the cause of gestational diabetes development. In addition to these, Yan et al. have demonstrated that up-regulation and down regulation of circular mRNA in placental villi of gestational diabetes patients, most of which had small miRNA binding sites, could have potential role in development of gestational diabetes (Yan et al., 2018).

The gene GCKR (glucokinase regulator) encodes a 68kD sugar isomerase (SIS) regulatory protein that inhibits glucokinase activity in hepatic and pancreatic β-cells by binding with the enzyme and relocating it to nucleus. The chromosomal location and gene properties are presented in Table 1. The role of GCKR has been strongly associated with T2DM. Based on a case control meta-analytical study including genotype data of 1122 women, Jamalpour et al. observed a strong association of GCKR rs780094-C with higher risk of gestational diabetes (Jamalpour, Zain, Mosavat, Mohamed, & Omar, 2018).

Chimerin has been regarded as one of the metabolic mediator in the development of insulin resistance. Hasanvand et al. observed an association between Chimerin SNPs rs4721 and the risk for developing gestational diabetes among Iranian women (Hasanvand et al., 2018). TCF7L2 (transcription factor 7 like 2) encodes for a transcription factor involved in Wnt signaling pathway regulating blood glucose homeostatis. Franzago et al. observed that genetic variant - rs7903146 (C>T) in TCF7L2 gene was strongly associated with the risk of developing gestational diabetes while polymorphism in PPARG2 gene was found to be strongly correlated with lipid parameters (Franzano et al., 2018).

Macrophage migration inhibitory factor (MIF) gene encodes lymphokine involved in macrophage function and inflammation. Zheng et al. have revealed that enhanced expression of MIF gene in placental tissue correlated with insulin resistance and incidence of gestational diabetes among Chinese Han population (Zheng et al., 2017). Alpha-2-adrenergic receptors (ADRA2A) gene encodes receptors that regulate neurotransmitter release from nerves. Kawai et al. have revealed that genetic variation in ADRA2A gene is independently associated with development of risk of gestational diabetes among Caucasian women (Kawai et al., 2017).

Kang et al. measured DNA methylation at 841,573 CpG sites and identified 200 loci of the genes in maternal and cord blood which were methylated differently in pregnant women with gestational diabetes, among which inflammatory pathways were identified (Kang, Lee, Li, Hsu, & Lin, 2017). Solute carrier family 6 member 4 (SLC6A4) encodes membrane protein that transports serotonin neurotransmitter from synaptic spaces into presynaptic neurons for reutilization. Blazevic et al. have noticed that DNA methylation of the fetal SLC6A4 gene is related to metabolic state in pregnant women. DNA methylation across seven loci was negatively correlated with plasma glucose levels at 28th week of gestation. Paired box gene (PAX) encodes a family of transcription factors which are involved in differentiation and development of pancreatic β-cells. Xu et al. have observed that polymorphism in rs10229583 near paired box gene (PAX) is associated with gestational diabetes among Chinese women wherein GG genotype frequency was significantly different between gestational diabetes and normal
subjects (Xu et al., 2018). Based on a study comprising of 204 pregnant women with gestational diabetes, Tarnowski et al. have found that polymorphisms in pro-inflammatory cytokine genes (IL18 rs187238 and rs1946518) were associated with higher risk of gestational diabetes (Tarnowski et al., 2017).

**Genome wide association studies of diabetes condition**

Genomic studies have revealed that mutations in genes distributed across chromosomes were associated with different types of diabetes such as T1DM, T2DM, gestational diabetes and MODY (Kota, Meher, Jammula, Kota, & Modi, 2012). The distribution of the genes involved in development of different types of diabetes is presented in Table 1. Chromosome number 6 and 11 harbors the maximum number of genes (6), each associated with different types of diabetes. This is followed by chromosome number 2 carrying 5 diabetes related genes. Chromosome 3 has 4 genes while chromosome 10, 12, 13 and 20 have 2 genes each. Chromosome 1, 4, 8, 9, 17 and X chromosome contain 1 gene each.

Out of all the 39 genes evaluated, 10 genes were related to immunological function, 17 genes were involved in metabolic function and 12 genes have genetic regulatory roles. The length of the gene ranged from a minimum of 687 base pairs for small ubiquitin-like modifier 4 (SUMO4) gene located on the long arm of chromosome number 6 to maximum of 697947 base pairs for CDK5 regulatory subunit associated protein 1 like 1 (CDKAL1) gene located on small arm of chromosome number 6. The number of exons ranged from a minimum of 1 exon in SUMO4 to a maximum of 60 exons in ITPR3 gene located on small arm of chromosome number 6. Except chromosome number 1 and X chromosome, all other chromosomes had genes related to more than one type of diabetes. A total of 15 genes were linked to T1DM while only 5 genes were associated with T2DM. Gestational diabetes was related to 9 genes while 14 genes were related to MODY. It is interesting to note that mutation in IRS1 gene located on chromosome number 2 was responsible for both T1DM and gestational diabetes. HNF1A gene on long arm of chromosome number 12 was linked to three different types of diabetes namely T1DM, T2DM and MODY3. HNF4A gene located on the long arm of chromosome number 20 was linked to two different types of diabetes namely T2DM and gestational diabetes. Maximum heterogeneity with regard to the genes related to different types of diabetes was found with chromosome number 3 that contained genes related to all four types of diabetes (Table 1).

Considering the genes encoding protein with genetic role in the manifestation of the risk in different types of diabetes, it was found that a greater number of genes were associated with MODY followed by gestational diabetes, T2DM and T1DM (Figure 3). Single nucleotide polymorphism in about thirteen genes were relevant for MODY while the number of genes relevant to the manifestation of gestational diabetes, T2DM and T1DM were 4, 3 and 1, respectively. It is interesting to note that HNF4A gene located in the position 20q13.12 was common for gestational diabetes, MODY and T2DM.

HNF1A gene located in the position of 12q24.31 was common for the risk of MODY, T1DM and T2DM. Considering the genes encoding protein that have metabolic function, it was observed that a maximum of 10 genes were associated with the risk of MODY followed by 5 genes related to the risk of gestational diabetes, 4 genes relevant to the risk of T1DM and 2 genes related to T2DM. GCK gene located on 7p13 position, KCNJ11 located at 11p15.1 was common for gestational diabetes and MODY. IRS1 located at 2q36.3 was common for gestational diabetes and T2DM. With regard to the genes encoding protein having immunological function, a maximum of 10 genes were associated with the risk of T1DM. It is interesting to note that among major protein encoding genes with immunological role in which SNP has profound influence on the risk of diabetes were all solely related to T1DM. Probably, this is the reason why T1DM is also termed as autoimmune disease.
The risk of SNP is directly proportional to the number of exons as the risk of exposure for mutations is high. The risk of SNP is indirectly proportional to the length of the gene, since greater length with higher number of introns poses lesser risk of mutation in the protein encoded. Therefore, the risk for the protein encoding genes was
derived as ratio of the number of exons to the length of the gene. It was observed that INS gene located on the chromosome 11 has greater susceptibility to mutation with the risk ratio value of 0.0020, followed by PAX4 gene located on chromosome 7 with a value of 0.0015 and SUMO4 gene located on chromosome 6 with a value of 0.0014. The relative risk for the rest of the genes was presented in Figure 4. It can be noted that INS gene has direct relevance to diabetes as the gene encodes the hormone insulin which facilitates the utilization of glucose by the peripheral tissues thus reducing the blood glucose level. Mutation in INS gene may lead to elevated blood glucose level.

Figure 4. Relative risk factor for the protein encoding genes. Risk factors were calculated as ratio of number of exons to gene length.

The distribution of the genes which are relevant to different types of diabetes on different chromosomes is presented in Figures 5A-5C. Only two or more genes present on single chromosome were represented. Chromosome number 1, 4, 8, 9, 17 and X harbored only single risk gene. Chromosome number 2 has 5 genes with metabolic, immunological and genetic effects. Chromosome number 3 has 4 genes with all the three categories of effects. Chromosome 6 has 6 genes with all three functional effects. Similarly, chromosome number 7 has 4 genes with all three functional effects. Chromosome number 10 has 3 genes with genetic and immunological effects. It is interesting to note that chromosome number 11 has 5 genes, all with metabolic relevance only. Chromosome 12, 13 and 20 have 2 genes each with common genetic effects. It is important to note that IRS1 gene located on chromosome number 2 is a risk factor for both T1DM and gestational diabetes, while HNF1A gene located on chromosome number 12 is a genetic risk factor for T1DM, T2DM and MODY3.
Diabetes mellitus types: Key genetic determinants and risk assessment

![Diagram of chromosome distribution for types of diabetes on chromosomes 2, 3, and 6.](image1)

**Figure 5A.** Distribution of genes relevant to different types of diabetes on chromosome number 2, 3, and 6.

![Diagram of chromosome distribution for types of diabetes on chromosomes 7, 10, and 11.](image2)

**Figure 5B.** Distribution of genes relevant to different types of diabetes on chromosome number 7, 10, 11.
Figure 5C. Distribution of genes relevant to different types of diabetes on chromosome number 12, 13 and 20.

**Epigenetic regulation of diabetic condition**

Several dietary and environmental factors, both biotic and abiotic have been implicated in the epigenetic modifications. Viral infections and toxins also alter the routine metabolism that may predispose for epigenetic changes. These changes affect the genes by inducing either allele polymorphism mediated susceptibility or resistance to disease conditions (Desiderio et al., 2016; Zullo et al., 2017). Metabolic compounds such as S-adenosylmethionine, acetyl-CoA, nicotinamide adenine dinucleotide, α-ketoglutarate, and adenosine triphosphate function as cofactors for methyltransferases, deacetylases and kinases which modify chromatin. Dietary components such as free fatty acids, amino acids, glucose, glutamine, etc., modulate epigenetics (Etchegaray & Mostoslavsky, 2016). Aberrant toll-like receptor (TLR) signaling causes autoimmune response leading to development of T1DM. Epigenetic changes alter TLR signaling leading to T1DM (Xie et al., 2018). BCG vaccination was found to reduce long term hyperglycemia in T1DM patients. BCG vaccination was found to epigenetically reset T regulatory genes with genetic reprogramming of tolerance and induce aerobic glycolysis resulting in glucose homeostasis (Kuhtreiber et al., 2018). MicroRNAs are small non-coding RNA that regulates gene expression. During the onset of T1DM, overexpression of miR-487a-3p was noted that repress *CTLA4* and *FOXO3* by binding to their 3'UTRs and thus resulting in manifestation of T1DM (Zurawek et al., 2018).

DNA methylation has been found as a key mechanism for instigation of T2DM affecting both insulin secretion as well as insulin sensitivity. Zhou et al. have described 17 different genes that are involved in epigenetic manifestation of T2DM (Zhou, Sun, Li, & Zhu, 2018). Out of them two genes (insulin and metformin transporter genes) in islet and liver respectively were found susceptible to demethylation. Four out of the seventeen genes (*LINE-1, MCP-1, TXNIP, NR4A1*) in peripheral blood were susceptible to hypomethylation. *PPARGC1A, KCNQ1,* Insulin gene, *PDX-1, GLP1R, MEG3-DLK1* microRNA, *NDUFB6, COX7A1, IGFBP1* and *IGFBP7,* Alu repeats, *TCF7L2* belonging to different cell types were susceptible to hypermethylation. Insulin gene, *PPARGC1A, PDX-1, MEG3-DLK1* and microRNA were associated with insulin secretion. *NDUFB6, COX7A1, IGFBP1, IGFBP7* and Alu repeats were associated with insulin sensitivity. Metformin transporter genes, *KCNQ1,* Insulin gene, *GLP1R, TCF7L2, LINE-1, MCP-1, TXNIP* and *NR4A1* were associated with glycemic metabolism. Methylation of mitochondrial DNA has been regarded as the most prominent in microvascular complication of T2DM (Rorbach-Dolata, Kubis, & Piwowar, 2017). Acetylation of arginine and lysine among histone proteins was observed as an important epigenetic modification, key to the development of T2DM.
Genetic challenges, success and future directions in mitigating diabetic condition

Recently, GWAS studies revealed over 60 susceptible genes marked with SNPs that participate in gene regulatory network in manifestation of T1DM (Nyaga, Vickers, Jefferies, Perry, & O’Sullivan, 2018). About 80% of the genetic heritability of T1DM can be explained with GWAS data (Pociot et al., 2010). However, most of the associated variants are present in the non-coding region. Within immune system domain, about 56 genetic risk variants were found to be associated with T1DM out of which 11 were shared with endothelial functioning and 2 were shared with islet functioning. Endothelial and pancreatic islets have 2 exclusive genetic risk factors each with relevance to T1DM (Wallet, Santostefano, Terada, & Brusko, 2017). The risk associated with non-immunogenic genes is relatively less. However, a large number of variants with low frequency may influence the autoimmune functioning and thus the manifestation of T1DM. One such risk locus is UBASH3A gene located on chromosome 21q22.3. that inhibits NF-κB signaling (Ge & Concannon, 2018). In the MHC region, rs9260151 and rs3135002 have been linked with the risk of T1DM (Roshandel et al., 2018). In a different study, Erb-b2 receptor tyrosine kinase 3 (ERBB3) rs2292239 SNP was found to be associated with risk for T1DM in a white Brazilian population and has been identified as a susceptibility locus for T1DM (Lemos et al., 2018). Zhu et al. have emphasized that induction of immune tolerance together with genetic engineering could be beneficial in islet transplantation in pancreas as cellular replacement therapy for T1DM (Zhu et al., 2018).

It was found that monogenic forms of diabetes such as MODY can be treated with good precision. However, it was found that the prevalence of monogenic diabetes was found to be different across different geographical regions and demographics. Therefore, it is important to widely characterize the genetic basis of monogenic diabetes to accurately differentiate from other forms of adult onset diabetes. Intolerance towards β-cell antigen is the main reason for instigation of T1DM. For this, antigen specific immunotherapy confers immune tolerance either by supply of specific antigens that are tolerated or by promoting tolerance responses. Creusot et al. have identified that alteration in the functioning of the antigen presenting cells in T1DM as affected by genetic polymorphism is a challenge for antigen specific immunotherapy of T1DM (Creusot, Postigo-Fernandez, & Teteloshvili, 2018). The study emphasized on better characterization of such alterations for devising efficient methods for antigen tolerance.

Meta-analysis considering multiple factors is essential for understanding the associations of the genes by combining different studies. Case control ratio influences the power and reliability of the outcome. Yang et al. proposed a novel approach by incorporating adjustments for population stratification by correcting for known population structure through minor allele frequencies and emphasized its applicability for both single gene and gene level association studies (Yang, Chen, & Abecasis, 2018).

CONCLUSION

Epigenetic factors and non-immunogenic genetic factors seem to pose lower risk when compared to immunogenic genetic determinants in the manifestation of T1DM. It remains to be inferred, whether the genetic susceptibility or the risk factors associated with autoimmune mechanism is more prominent in the manifestation of T1DM than epigenetic causes. The probability of effective genetic therapy is high for single gene involvement when compared to polygenic involvement. Particularly, T1DM has involvement of multiple genes with immunological role. Therefore, identification of specific genetic targets in polygenic cases seems to be ineffective. However, T1DM is associated with insulin secretion which is a function of single type of cells. Therefore, the study of genes associated with islet functioning such as SLC30A8, DDX1, SRp55 would bring in certain degree of specificity to preserve and sustain β-cells and their insulin secretion potential. The factors that preserve the beta cell functioning, suppression of autoimmune response towards islets need to be identified and characterized for effective prevention of T1DM. As there are susceptible alleles, there are also protective variants of genes associated with T1DM such as A/G splice-site single nucleotide polymorphism (SNP: rs10774671) in OAS1 gene. Further exploration of beneficial polymorphisms associated with insulin secretion and insulin sensitivity need to be carried out. Epigenetic changes have role in instigation of diabetes; hence, epigenetic drugs may have substantial effect on the prevention and treatment of T1DM. Manifestation of T2DM is associated with multiple genes. Compared to other forms of diabetes, the genetic risk factors with genetic and metabolic functioning for the manifestation of T2DM are
relatively lower. However, the incidence of T2DM constitutes over 90% of all the cases. This reveals that the interaction between the genetic constitution and environment is more substantial and probability of T2DM increases with higher environmental/dietary risk. The degree of such interaction is variable with geography and population. Therefore, characterization of genetic variants in association with population, their diet patterns and demographic features is essential. MODY has largest number of genetic risk determinants with genetic and metabolic functions. Further exploration of familial mono-genic variants across populations would provide deeper insights. The genes relevant to gestational diabetes were not distributed in chromosome 1, 12, 17 and X, where genes for other types of diabetes were located. In chromosome 3, genetic risk factor is located on q arm and the genetic risk factors for other types of diabetes are located on p arm. Except in chromosome 20 (where functional association between MODY, T2DM and gestational diabetes was observed), the genes associated with gestational diabetes were mostly co-distributed with the genes for T1DM and MODY. Genetic maps reveal that there is greater variability in the distribution and positional linkage as well as functional proximity among genetic risk factors associated with different types of diabetes. Probably this is the reason why there were no effective genetic therapies that could be designed so far.

REFERENCES


Hashemzadeh AA, Nasoohi N, Raygan F, Aghadavod E, et al. (2017) Flaxseed Oil Supplementation Improve Gene Expression Levels of PPAR-gamma, LP (a), IL-1 and TNF-alpha in Type 2 Diabetic Patients with Coronary Heart Disease. Lipids 52: 907-915. https://doi.org/10.1007/s11745-017-4295-5


